Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. But, as an end-of -decade patent cliff approaches, the company is turning to new potential growth drivers to make up for the looming loss. 

The US FDA has granted approval to Niktimvo for the treatment of chronic graft-versus-host disease, a serious immune condition affecting the recipients of stem cell transplants.

The U.S. Food and Drug Administration on Wednesday approved Incyte's (INCY.O) treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.